Pharmacoeconomics of liposomal anthracycline therapy

被引:11
作者
Bennett, CL
Calhoun, EA
机构
[1] Northwestern Univ, Vet Affairs Chicago Healthcare Syst Lakeside, Chicago, IL 60611 USA
[2] Northwestern Univ, Inst Hlth Serv & Policy Studies, Chicago, IL 60611 USA
关键词
D O I
10.1053/j.seminoncol.2004.08.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pharmacoeconomic analyses are being used with greater frequency in clinical oncology trials. These analyses provide guidelines for prioritizing competing interventions and allocating health care resources, particularly when deciding whether to use a drug with a higher acquisition cost. For liposomal anthracyclines, the competing treatments are other liposomal anthracyclines and nonliposomal chemotherapy agents with similar activity. Pharmacoeconomic analyses of data from clinical trials in patients with Kaposi's sarcoma determined that the overall cost to achieve objective response was substantially lower with pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]) than with liposomal daunorubicin (DaunoXome [DNX]). Additional economic analyses in patients with ovarian cancer showed that PLD has lower overall treatment costs than topotecan because it is administered less frequently and requires fewer interventions for toxicity. The decision to allocate health care resources to liposomal anthracycline treatment must therefore include consideration of cost-effectiveness and potential cost savings owing to improved tolerability. © 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:191 / 195
页数:5
相关论文
共 26 条
[11]  
Freund D A, 1992, Pharmacoeconomics, V1, P20, DOI 10.2165/00019053-199201010-00006
[12]  
*GIL SCI INC, 2002, DAUN DAUN CITR LIP I
[13]   Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma [J].
Gill, PS ;
Wernz, J ;
Scadden, DT ;
Cohen, P ;
Mukwaya, GM ;
vonRoenn, JH ;
Jacobs, M ;
Kempin, S ;
Silverberg, I ;
Gonzales, G ;
Rarick, MU ;
Myers, AM ;
Shepherd, F ;
Sawka, C ;
Pike, MC ;
Ross, ME .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (08) :2353-2364
[14]   Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan [J].
Gordon, AN ;
Fleagle, JT ;
Guthrie, D ;
Parkin, DE ;
Gore, ME ;
Lacave, AJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) :3312-3322
[15]   Pharmacoeconomics and health policy - Current applications and prospects for the future [J].
Greenberg, PE ;
Arcelus, A ;
Birnbaum, HG ;
Cremieux, PY ;
LeLorier, J ;
Ouellette, P ;
Slavin, MB .
PHARMACOECONOMICS, 1999, 16 (05) :425-432
[16]   The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients [J].
Hensley, ML ;
Hoppe, B ;
Leon, L ;
Sabbatini, P ;
Aghajanian, C ;
Chi, D ;
Spriggs, DR .
GYNECOLOGIC ONCOLOGY, 2001, 82 (03) :464-469
[17]  
Hjortsberg C, 1999, ACTA ONCOL, V38, P1063
[18]  
HUSSEIN MA, 2004, P AN M AM SOC CLIN, V23, P567
[19]   GUIDELINES FOR PERFORMING A PHARMACOECONOMIC ANALYSIS [J].
JOLICOEUR, LM ;
JONESGRIZZLE, AJ ;
BOYER, JG .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1992, 49 (07) :1741-1747
[20]  
OBRYNE KJ, 2002, P AN M AM SOC CLIN, V21, pA203